Literature DB >> 18635825

G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.

Philip W Raake1, Leif E Vinge, Erhe Gao, Matthieu Boucher, Giuseppe Rengo, Xiongwen Chen, Brent R DeGeorge, Scot Matkovich, Steven R Houser, Patrick Most, Andrea D Eckhart, Gerald W Dorn, Walter J Koch.   

Abstract

Myocardial G protein-coupled receptor kinase (GRK)2 is a critical regulator of cardiac beta-adrenergic receptor (betaAR) signaling and cardiac function. Its upregulation in heart failure may further depress cardiac function and contribute to mortality in this syndrome. Preventing GRK2 translocation to activated betaAR with a GRK2-derived peptide that binds G(beta)gamma (betaARKct) has benefited some models of heart failure, but the precise mechanism is uncertain, because GRK2 is still present and betaARKct has other potential effects. We generated mice in which cardiac myocyte GRK2 expression was normal during embryonic development but was ablated after birth (alphaMHC-Cre x GRK2 fl/fl) or only after administration of tamoxifen (alphaMHC-MerCreMer x GRK2 fl/fl) and examined the consequences of GRK2 ablation before and after surgical coronary artery ligation on cardiac adaptation after myocardial infarction. Absence of GRK2 before coronary artery ligation prevented maladaptive postinfarction remodeling and preserved betaAR responsiveness. Strikingly, GRK2 ablation initiated 10 days after infarction increased survival, enhanced cardiac contractile performance, and halted ventricular remodeling. These results demonstrate a specific causal role for GRK2 in postinfarction cardiac remodeling and heart failure and support therapeutic approaches of targeting GRK2 or restoring betaAR signaling by other means to improve outcomes in heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635825      PMCID: PMC2679955          DOI: 10.1161/CIRCRESAHA.107.168336

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  39 in total

1.  Effects of chronic beta-adrenergic receptor stimulation in mice.

Authors:  R K Kudej; M Iwase; M Uechi; D E Vatner; N Oka; Y Ishikawa; R P Shannon; S P Bishop; S F Vatner
Journal:  J Mol Cell Cardiol       Date:  1997-10       Impact factor: 5.000

2.  Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo.

Authors:  R Agah; P A Frenkel; B A French; L H Michael; P A Overbeek; M D Schneider
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Why does the myocardium fail? Insights from basic science.

Authors:  M R Bristow
Journal:  Lancet       Date:  1998-08       Impact factor: 79.321

4.  Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice.

Authors:  M H Gao; N C Lai; D M Roth; J Zhou; J Zhu; T Anzai; N Dalton; H K Hammond
Journal:  Circulation       Date:  1999-03-30       Impact factor: 29.690

5.  Low- and high-level transgenic expression of beta2-adrenergic receptors differentially affect cardiac hypertrophy and function in Galphaq-overexpressing mice.

Authors:  G W Dorn; N M Tepe; J N Lorenz; W J Koch; S B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

6.  Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.

Authors:  Patrick Most; Hanna Seifert; Erhe Gao; Hajime Funakoshi; Mirko Völkers; Jörg Heierhorst; Andrew Remppis; Sven T Pleger; Brent R DeGeorge; Andrea D Eckhart; Arthur M Feldman; Walter J Koch
Journal:  Circulation       Date:  2006-09-04       Impact factor: 29.690

7.  Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling.

Authors:  Scot J Matkovich; Abhinav Diwan; Justin L Klanke; Daniel J Hammer; Yehia Marreez; Amy M Odley; Eric W Brunskill; Walter J Koch; Robert J Schwartz; Gerald W Dorn
Journal:  Circ Res       Date:  2006-09-28       Impact factor: 17.367

8.  Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function.

Authors:  M Jaber; W J Koch; H Rockman; B Smith; R A Bond; K K Sulik; J Ross; R J Lefkowitz; M G Caron; B Giros
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

9.  Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor.

Authors:  C A Milano; L F Allen; H A Rockman; P C Dolber; T R McMinn; K R Chien; T D Johnson; R A Bond; R J Lefkowitz
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

10.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice.

Authors:  H A Rockman; K R Chien; D J Choi; G Iaccarino; J J Hunter; J Ross; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

View more
  114 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

2.  G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.

Authors:  Michele Ciccarelli; J Kurt Chuprun; Giuseppe Rengo; Erhe Gao; Zhengyu Wei; Raymond J Peroutka; Jessica I Gold; Anna Gumpert; Mai Chen; Nicholas J Otis; Gerald W Dorn; Bruno Trimarco; Guido Iaccarino; Walter J Koch
Journal:  Circulation       Date:  2011-04-25       Impact factor: 29.690

Review 3.  Model-specific selection of molecular targets for heart failure gene therapy.

Authors:  Michael G Katz; Anthony S Fargnoli; Catherine E Tomasulo; Louella A Pritchette; Charles R Bridges
Journal:  J Gene Med       Date:  2011-10       Impact factor: 4.565

Review 4.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

Review 5.  GRK mythology: G-protein receptor kinases in cardiovascular disease.

Authors:  Gerald W Dorn
Journal:  J Mol Med (Berl)       Date:  2009-02-20       Impact factor: 4.599

Review 6.  Rescuing the failing heart by targeted gene transfer.

Authors:  Yoshiaki Kawase; Dennis Ladage; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2011-03-08       Impact factor: 24.094

Review 7.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

Review 8.  Gene therapy targets in heart failure: the path to translation.

Authors:  P W J Raake; H Tscheschner; J Reinkober; J Ritterhoff; H A Katus; W J Koch; P Most
Journal:  Clin Pharmacol Ther       Date:  2011-08-24       Impact factor: 6.875

Review 9.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

Review 10.  Regulatory SNPs and transcriptional factor binding sites in ADRBK1, AKT3, ATF3, DIO2, TBXA2R and VEGFA.

Authors:  Norman E Buroker
Journal:  Transcription       Date:  2014-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.